Targeted Adjuvant Therapies Provide No Survival Benefit in Stage III Melanoma

Source: Cancer Therapy Advisor, June 2023

Targeted adjuvant therapy does not improve outcomes in patients with stage III melanoma, according to a Swedish study published in the Journal of the National Cancer Institute.

Researchers found that patients with stage III melanoma had similar overall survival and melanoma-specific survival whether they were diagnosed before or after the introduction of adjuvant targeted therapies for melanoma in Sweden.

This retrospective study included all patients diagnosed with stage III melanoma in Sweden from 2016 through 2020. The patients were divided based on whether they were diagnosed before or after July 2018, which was when the European Medicines Agency approved adjuvant nivolumab and adjuvant dabrafenib and trametinib for patients with melanoma.